Broadcast videos

CRISPR, a pioneering genome-editing technique, technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.

CRISPR, a pioneering genome-editing technique, technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.

Gothenburg, Sweden is one of our three strategic global R&D centres with connections to Karolinska Institutet and Medicon Valley. Södertälje is one of our principal small molecule manufacturing facilities.

We are a global, innovation-driven biopharmaceutical business. We push the boundaries of science to deliver medicines that transform the lives of people around the world.

Macclesfield, in the north-west of England, is our second largest global manufacturing site and our European centre for packing. In 2013 we announced plans to invest $190 million to construct a new facility to continue production of Zoladex.